Keeps Biopharma Inc. (KOSDAQ:256940)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,440.00
-210.00 (-3.16%)
At close: May 29, 2026

Keeps Biopharma Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
22,30322,04418,7774,10623,62537,197
Short-Term Investments
6,1081,8793,934756.56303,092
Trading Asset Securities
2,6492,649276.086,0471,549600.6
Cash & Short-Term Investments
31,06026,57122,98810,91025,20340,889
Cash Growth
28.98%15.59%110.71%-56.71%-38.36%28.98%
Accounts Receivable
31,29620,97916,2569,6776,1946,718
Other Receivables
-288.65460.571,925212.39332.01
Receivables
31,29621,26716,71613,2466,40712,850
Inventory
29,41931,52420,4365,3281,6022,246
Prepaid Expenses
-633.76828.01113.0653.642.96
Other Current Assets
24,84422,3869,74617,16910,0447,315
Total Current Assets
116,619102,38270,71446,76643,31063,342
Property, Plant & Equipment
45,19643,63635,06828,37610,06210,365
Long-Term Investments
8,91510,29715,1109,21618,36916,906
Goodwill
-29,51629,25023,970--
Other Intangible Assets
52,30321,90511,5146,596958.46965.41
Long-Term Accounts Receivable
---0129.69361.77
Long-Term Deferred Tax Assets
--312.111,528--
Other Long-Term Assets
20,84524,5735,021826.236,3671,462
Total Assets
243,878233,917166,989117,27985,55993,401
Accounts Payable
10,0223,9155,9252,765630.13768.35
Accrued Expenses
-2,4321,9691,956744.98901.09
Short-Term Debt
42,65835,06641,64047,90428,12426,755
Current Portion of Long-Term Debt
1,1809,693330.72---
Current Portion of Leases
681.47333.82276.49308.59310.16276.52
Current Income Taxes Payable
553.18697.832,991---
Other Current Liabilities
37,33937,27132,6612,9462,2501,496
Total Current Liabilities
92,43489,40785,79355,88032,05930,197
Long-Term Debt
50,05647,34713,427---
Long-Term Leases
202.94153.6762.8591.93386.34571.69
Pension & Post-Retirement Benefits
616.22237.46424.77525.41--
Long-Term Deferred Tax Liabilities
5,1285,2322,526356.28248.32766.68
Other Long-Term Liabilities
10,21010,0371,3401,846597.55978.75
Total Liabilities
158,647152,415103,57458,69933,29132,514
Common Stock
10,03910,0399,3749,3749,3749,268
Additional Paid-In Capital
46,36061,66536,80667,86667,69164,242
Retained Earnings
3,196-2,4697,270-23,631-27,455-15,188
Comprehensive Income & Other
7,044-7,224-3,3173,6273,4622,704
Total Common Equity
66,64062,01150,13457,23653,07261,026
Minority Interest
18,59119,49213,2821,343-804.49-139.37
Shareholders' Equity
85,23181,50363,41558,57952,26860,887
Total Liabilities & Equity
243,878233,917166,989117,27985,55993,401
Total Debt
94,77992,59355,73748,30428,82027,603
Net Cash (Debt)
-63,720-66,022-32,749-37,395-3,61713,286
Net Cash Growth
-----21.17%
Net Cash Per Share
-3192.37-3365.52-1735.34-1987.66-193.02767.26
Filing Date Shares Outstanding
20.2420.0818.7518.7518.7518.54
Total Common Shares Outstanding
20.2420.0818.7518.7518.7518.54
Working Capital
24,18412,974-15,079-9,11411,25133,145
Book Value Per Share
3292.393088.472673.993052.822830.713292.31
Tangible Book Value
14,33610,5909,37026,67152,11460,061
Tangible Book Value Per Share
708.29527.42499.751422.532779.593240.22
Land
-20,92313,66312,7103,0223,022
Buildings
-12,83816,94316,1906,9536,953
Machinery
-22,99720,99115,3123,3433,283
Construction In Progress
-5,3452,886---